首页 > 最新文献

JTCVS open最新文献

英文 中文
Mid-term valve performance and durability of the Ozaki procedure in patients on chronic dialysis 慢性透析患者Ozaki手术的中期瓣膜性能和持久性
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-02-12 DOI: 10.1016/j.xjon.2026.101677
Nika Samadzadeh Tabrizi MD, Yasuhiro Hoshino MD, PhD, Shinya Unai MD, Hiromasa Hayama MD, Mikio Takatoo MD, Nagaki Kiyohara MD, Masami Goda MD, Schinichiro Shimura MD, PhD, Shiho Ide MD, Takuto Naiki MD, William C. Frankel MD, Matthew A. Thompson MD, Xiaowen Li MS, Jeevanantham Rajeswaran PhD, Eugene H. Blackstone MD, Gösta B. Pettersson MD, PhD, Shigeyuki Ozaki MD, PhD

Objective

To compare the hemodynamic performance and durability of the Ozaki procedure in patients with end-stage renal disease on chronic dialysis between patients not on dialysis and patients on dialysis undergoing bioprosthetic aortic valve replacement (bAVR).

Methods

Between January 1, 2007, and May 1, 2021, 155 adults on dialysis underwent the Ozaki procedure at Toho University Ohashi Medical Center. Mean aortic valve gradient, aortic regurgitation grade, and freedom from reoperation were compared between 121 propensity score–matched patients not on dialysis undergoing the Ozaki procedure and 125 age-matched patients on dialysis undergoing valve replacement with a stented bovine pericardial bioprosthesis at Cleveland Clinic between January 1, 2001, and January 1, 2022.

Results

Five years after the Ozaki procedure, matched patients on dialysis were less likely to have moderate/severe regurgitation (1.7%) compared to those not on dialysis (4.1%). In the 2 groups, mean aortic gradient was 7 mmHg and 9 mm Hg, respectively (P = .06), and freedom from aortic valve reoperation was 91% and 96%, respectively (P = .4). Age-matched patients on dialysis undergoing the Ozaki procedure and those undergoing bAVR had a mean gradient of 9 mm Hg and 13 mm Hg, respectively, at 6 months (P < .001) and 11 mm Hg and 14 mm Hg at 5 years (P < .001). At 5 years, the prevalence of moderate/severe regurgitation was 1.3% and 2.0%, and freedom from reoperation was 91% and 96% (P = .4).

Conclusions

In patients on chronic dialysis undergoing the Ozaki procedure, hemodynamics and durability are similar compared with those not on dialysis, and mean gradients are lower compared with those receiving a bioprosthesis. These findings support use of the Ozaki procedure in patients on dialysis requiring aortic valve replacement.
目的比较非透析患者和透析患者行生物人工主动脉瓣置换术(bAVR)的终末期肾脏疾病慢性透析患者的Ozaki手术的血流动力学性能和持久性。方法:在2007年1月1日至2021年5月1日期间,155名透析成人在东宝大学大桥医学中心接受了Ozaki手术。研究人员比较了2001年1月1日至2022年1月1日克利夫兰诊所121名倾向评分匹配的非透析患者接受Ozaki手术和125名年龄匹配的透析患者接受支架牛心包生物假体瓣膜置换术的平均主动脉瓣梯度、主动脉反流等级和再次手术的自由度。结果Ozaki手术后5年,接受透析的匹配患者发生中度/重度反流的可能性(1.7%)低于未接受透析的患者(4.1%)。两组患者主动脉梯度平均值分别为7mmhg和9mmhg (P = 0.06),主动脉瓣再手术成功率分别为91%和96% (P = 0.04)。年龄匹配的接受Ozaki手术的透析患者和接受bAVR的患者在6个月时的平均梯度分别为9 mm Hg和13 mm Hg (P < 0.001),在5年时的平均梯度为11 mm Hg和14 mm Hg (P < 0.001)。5年时,中/重度反流发生率分别为1.3%和2.0%,再次手术成功率分别为91%和96% (P = 0.4)。结论在接受Ozaki手术的慢性透析患者中,血液动力学和持久性与未接受透析的患者相似,平均梯度低于接受生物假体的患者。这些发现支持在需要主动脉瓣置换术的透析患者中使用Ozaki手术。
{"title":"Mid-term valve performance and durability of the Ozaki procedure in patients on chronic dialysis","authors":"Nika Samadzadeh Tabrizi MD,&nbsp;Yasuhiro Hoshino MD, PhD,&nbsp;Shinya Unai MD,&nbsp;Hiromasa Hayama MD,&nbsp;Mikio Takatoo MD,&nbsp;Nagaki Kiyohara MD,&nbsp;Masami Goda MD,&nbsp;Schinichiro Shimura MD, PhD,&nbsp;Shiho Ide MD,&nbsp;Takuto Naiki MD,&nbsp;William C. Frankel MD,&nbsp;Matthew A. Thompson MD,&nbsp;Xiaowen Li MS,&nbsp;Jeevanantham Rajeswaran PhD,&nbsp;Eugene H. Blackstone MD,&nbsp;Gösta B. Pettersson MD, PhD,&nbsp;Shigeyuki Ozaki MD, PhD","doi":"10.1016/j.xjon.2026.101677","DOIUrl":"10.1016/j.xjon.2026.101677","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the hemodynamic performance and durability of the Ozaki procedure in patients with end-stage renal disease on chronic dialysis between patients not on dialysis and patients on dialysis undergoing bioprosthetic aortic valve replacement (bAVR).</div></div><div><h3>Methods</h3><div>Between January 1, 2007, and May 1, 2021, 155 adults on dialysis underwent the Ozaki procedure at Toho University Ohashi Medical Center. Mean aortic valve gradient, aortic regurgitation grade, and freedom from reoperation were compared between 121 propensity score–matched patients not on dialysis undergoing the Ozaki procedure and 125 age-matched patients on dialysis undergoing valve replacement with a stented bovine pericardial bioprosthesis at Cleveland Clinic between January 1, 2001, and January 1, 2022.</div></div><div><h3>Results</h3><div>Five years after the Ozaki procedure, matched patients on dialysis were less likely to have moderate/severe regurgitation (1.7%) compared to those not on dialysis (4.1%). In the 2 groups, mean aortic gradient was 7 mmHg and 9 mm Hg, respectively (<em>P</em> = .06), and freedom from aortic valve reoperation was 91% and 96%, respectively (<em>P</em> = .4). Age-matched patients on dialysis undergoing the Ozaki procedure and those undergoing bAVR had a mean gradient of 9 mm Hg and 13 mm Hg, respectively, at 6 months (<em>P</em> &lt; .001) and 11 mm Hg and 14 mm Hg at 5 years (<em>P</em> &lt; .001). At 5 years, the prevalence of moderate/severe regurgitation was 1.3% and 2.0%, and freedom from reoperation was 91% and 96% (<em>P</em> = .4).</div></div><div><h3>Conclusions</h3><div>In patients on chronic dialysis undergoing the Ozaki procedure, hemodynamics and durability are similar compared with those not on dialysis, and mean gradients are lower compared with those receiving a bioprosthesis. These findings support use of the Ozaki procedure in patients on dialysis requiring aortic valve replacement.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101677"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isolated or concomitant tricuspid valve surgery for massive or torrential tricuspid regurgitation 大面积或重度三尖瓣反流的单独或合并三尖瓣手术
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-06-27 DOI: 10.1016/j.xjon.2026.101944
Hironobu Sakurai MD, PhD, Satoshi Kainuma MD, PhD, Naonori Kawamoto MD, PhD, Kizuku Yamashita MD, PhD, Kota Suzuki MD, PhD, Takashi Kakuta MD, PhD, Ayumi Ikuta MD, PhD, Rieko Kutsuzawa MD, Yuki Tadokoro MD, Kazuki Miyatani MD, Shinichi Kurashima MD, Yuki Irie MD, Kenji Moriuchi MD, Masashi Amano MD, PhD, Atsushi Okada MD, PhD, Makoto Amaki MD, PhD, Hideaki Kanzaki MD, PhD, Takeshi Kitai MD, PhD, Chisato Izumi MD, PhD, Kazuhiro Yamamoto MD, PhD, Satsuki Fukushima MD, PhD

Objective

Massive or torrential tricuspid regurgitation is associated with poor survival; however, its impact on surgical results remains uncertain. Outcomes following tricuspid valve surgery in patients with severe versus massive or torrential tricuspid regurgitation were compared.

Methods

From 2010-2024, 164 symptomatic patients (mean age 71.2 ± 10.4 years) with severe (n = 69, 42%) or massive/torrential tricuspid regurgitation (n = 95, 58%) underwent tricuspid valve surgery, with or without concomitant procedures. Postoperative tricuspid regurgitation grade was the primary endpoint. Mortality and heart failure hospitalization predictors were analyzed. The mean follow-up was 4.6 ± 3.9 years.

Results

Tricuspid repair was performed more frequent in patients with severe than with massive/torrential tricuspid regurgitation (96% vs 80%, P = .004). In-hospital mortality rates were 0% and 2.1%, respectively (P = .506). Postoperatively, tricuspid regurgitation improved significantly in both groups, with similar rates of residual tricuspid regurgitation mild or less (73.9% vs 72.3%, P = .930). During the follow-up period, 26 patients died and 38 were re-hospitalized for heart failure. Five-year survival was similar between the groups (85% vs 81%, P = .358). Higher left ventricular ejection fraction (adjusted hazard ratio 0.97, P = .027) and estimated glomerular filtration rate (adjusted hazard ratio 0.98, P = .016) were independently protective for adverse outcomes, whereas baseline tricuspid regurgitation severity was not.

Conclusions

Tricuspid valve surgery for severe or massive/torrential tricuspid regurgitation can be performed with low perioperative mortality, and provides favorable long-term outcomes. Prognosis is determined primarily by baseline cardiac and renal function, rather than preoperative tricuspid regurgitation severity.
目的:三尖瓣严重或剧烈反流与生存不良相关;然而,其对手术结果的影响仍不确定。我们比较了三尖瓣手术后严重三尖瓣反流与大量三尖瓣反流或重度三尖瓣反流的结果。方法2010-2024年,164例重度(n = 69, 42%)或大面积/重度三尖瓣反流(n = 95, 58%)有症状的患者(平均年龄71.2±10.4岁)行三尖瓣手术,伴行或不伴行手术。术后三尖瓣反流等级为主要终点。分析死亡率和心力衰竭住院率的预测因素。平均随访4.6±3.9年。结果重度三尖瓣反流患者修复三尖瓣的频率高于重度三尖瓣反流患者(96% vs 80%, P = 0.004)。住院死亡率分别为0%和2.1% (P = .506)。两组术后三尖瓣返流明显改善,残余三尖瓣返流轻度或轻度发生率相似(73.9% vs 72.3%, P = 0.930)。在随访期间,26例患者死亡,38例因心力衰竭再次住院。两组5年生存率相似(85% vs 81%, P = .358)。较高的左心室射血分数(校正风险比0.97,P = 0.027)和估计的肾小球滤过率(校正风险比0.98,P = 0.016)对不良结局具有独立的保护作用,而基线三尖瓣反流严重程度则没有保护作用。结论对重度或大面积/重度三尖瓣反流患者行瓣膜手术治疗,围手术期死亡率低,远期预后良好。预后主要由基线心脏和肾脏功能决定,而不是术前三尖瓣反流严重程度。
{"title":"Isolated or concomitant tricuspid valve surgery for massive or torrential tricuspid regurgitation","authors":"Hironobu Sakurai MD, PhD,&nbsp;Satoshi Kainuma MD, PhD,&nbsp;Naonori Kawamoto MD, PhD,&nbsp;Kizuku Yamashita MD, PhD,&nbsp;Kota Suzuki MD, PhD,&nbsp;Takashi Kakuta MD, PhD,&nbsp;Ayumi Ikuta MD, PhD,&nbsp;Rieko Kutsuzawa MD,&nbsp;Yuki Tadokoro MD,&nbsp;Kazuki Miyatani MD,&nbsp;Shinichi Kurashima MD,&nbsp;Yuki Irie MD,&nbsp;Kenji Moriuchi MD,&nbsp;Masashi Amano MD, PhD,&nbsp;Atsushi Okada MD, PhD,&nbsp;Makoto Amaki MD, PhD,&nbsp;Hideaki Kanzaki MD, PhD,&nbsp;Takeshi Kitai MD, PhD,&nbsp;Chisato Izumi MD, PhD,&nbsp;Kazuhiro Yamamoto MD, PhD,&nbsp;Satsuki Fukushima MD, PhD","doi":"10.1016/j.xjon.2026.101944","DOIUrl":"10.1016/j.xjon.2026.101944","url":null,"abstract":"<div><h3>Objective</h3><div>Massive or torrential tricuspid regurgitation is associated with poor survival; however, its impact on surgical results remains uncertain. Outcomes following tricuspid valve surgery in patients with severe versus massive or torrential tricuspid regurgitation were compared.</div></div><div><h3>Methods</h3><div>From 2010-2024, 164 symptomatic patients (mean age 71.2 ± 10.4 years) with severe (n = 69, 42%) or massive/torrential tricuspid regurgitation (n = 95, 58%) underwent tricuspid valve surgery, with or without concomitant procedures. Postoperative tricuspid regurgitation grade was the primary endpoint. Mortality and heart failure hospitalization predictors were analyzed. The mean follow-up was 4.6 ± 3.9 years.</div></div><div><h3>Results</h3><div>Tricuspid repair was performed more frequent in patients with severe than with massive/torrential tricuspid regurgitation (96% vs 80%, <em>P</em> = .004). In-hospital mortality rates were 0% and 2.1%, respectively (<em>P</em> = .506). Postoperatively, tricuspid regurgitation improved significantly in both groups, with similar rates of residual tricuspid regurgitation mild or less (73.9% vs 72.3%, <em>P</em> = .930). During the follow-up period, 26 patients died and 38 were re-hospitalized for heart failure. Five-year survival was similar between the groups (85% vs 81%, <em>P</em> = .358). Higher left ventricular ejection fraction (adjusted hazard ratio 0.97, <em>P</em> = .027) and estimated glomerular filtration rate (adjusted hazard ratio 0.98, <em>P</em> = .016) were independently protective for adverse outcomes, whereas baseline tricuspid regurgitation severity was not.</div></div><div><h3>Conclusions</h3><div>Tricuspid valve surgery for severe or massive/torrential tricuspid regurgitation can be performed with low perioperative mortality, and provides favorable long-term outcomes. Prognosis is determined primarily by baseline cardiac and renal function, rather than preoperative tricuspid regurgitation severity.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101944"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of multiarterial versus single-arterial grafting in coronary artery bypass surgery 冠状动脉搭桥术中多动脉与单动脉移植的成本-效果
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-05-03 DOI: 10.1016/j.xjon.2026.101834
Niyi O. Odewade MD, Rami Bikdash BS, Ezra S. Brooks MD, Phoebe Otchere MD, MBA, Boateng Kubi MD, MPH, Marle Sabatino MD, Sameer Hirji MD, MPH, Thoralf M. Sundt MD, Asishana A. Osho MD, MPH, Ashraf A. Sabe MD, Antionia Kreso MD, Louis L. Nguyen MD, MBA, MPH

Objective

To evaluate the cost-effectiveness of multiarterial grafting (MAG) compared with single artery grafting (SAG) using institutional outcomes and a linked perioperative-chronic Markov model.

Methods

This was a retrospective cohort study of 3583 adults undergoing isolated coronary artery bypass grafting between 2008 and 2022 at 2 tertiary hospital centers. Operative and perioperative data were obtained from the institutional Society of Thoracic Surgeons database. Propensity score overlap weighting was used to balance baseline covariates. A 2-phase (30-day perioperative and 10-year chronic) Markov state-transition model, informed by weighted institutional outcomes and supplemented with national Society of Thoracic Surgeons and Centers for Medicare & Medicaid Services data, was used to estimate long-term costs and quality-adjusted life years.

Results

Among 3583 patients at 2 academic centers, MAG was associated with similar operative mortality and morbidity compared with SAG. In a linked perioperative-chronic Markov model, MAG yielded greater quality-adjusted survival (+0.241 quality-adjusted life-years) and lower 10-year discounted costs (–$7755 per patient). Sensitivity analyses demonstrated that MAG was not consistently cost-effective in the perioperative period but was robustly dominant in the chronic phase, with long-term results stable across a wide range of cost assumptions.

Conclusions

MAG was associated with comparable perioperative outcomes but improved quality-adjusted survival and lower long-term costs compared with SAG. Broader adoption of MAG could reduce health care expenditures while improving population health by addressing barriers to MAG use, particularly in women, minority patients, and socially vulnerable populations.
目的通过机构预后和围手术期-慢性马尔科夫模型比较多动脉移植(MAG)与单动脉移植(SAG)的成本-效果。方法回顾性队列研究了2008年至2022年间在2个三级医院中心接受孤立冠状动脉搭桥术的3583名成年人。手术和围手术期数据来自胸外科学会数据库。倾向评分重叠加权用于平衡基线协变量。采用两阶段(30天围手术期和10年慢性)马尔可夫状态过渡模型,以加权机构结果为依据,并辅以国家胸外科学会和医疗保险和医疗补助服务中心的数据,用于估计长期成本和质量调整生命年。结果在2个学术中心的3583例患者中,与SAG相比,MAG与相似的手术死亡率和发病率相关。在围手术期-慢性马尔可夫模型中,MAG产生更高的质量调整生存率(+0.241质量调整生命年)和更低的10年折扣成本(每位患者- 7755美元)。敏感性分析表明,MAG在围手术期并非始终具有成本效益,但在慢性期具有强大的优势,在广泛的成本假设范围内具有稳定的长期结果。结论:与SAG相比,mag与围手术期预后相当,但质量调整生存率更高,长期成本更低。更广泛地采用MAG可以减少卫生保健支出,同时通过解决使用MAG的障碍,特别是在妇女、少数民族患者和社会弱势群体中,改善人口健康。
{"title":"Cost-effectiveness of multiarterial versus single-arterial grafting in coronary artery bypass surgery","authors":"Niyi O. Odewade MD,&nbsp;Rami Bikdash BS,&nbsp;Ezra S. Brooks MD,&nbsp;Phoebe Otchere MD, MBA,&nbsp;Boateng Kubi MD, MPH,&nbsp;Marle Sabatino MD,&nbsp;Sameer Hirji MD, MPH,&nbsp;Thoralf M. Sundt MD,&nbsp;Asishana A. Osho MD, MPH,&nbsp;Ashraf A. Sabe MD,&nbsp;Antionia Kreso MD,&nbsp;Louis L. Nguyen MD, MBA, MPH","doi":"10.1016/j.xjon.2026.101834","DOIUrl":"10.1016/j.xjon.2026.101834","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the cost-effectiveness of multiarterial grafting (MAG) compared with single artery grafting (SAG) using institutional outcomes and a linked perioperative-chronic Markov model.</div></div><div><h3>Methods</h3><div>This was a retrospective cohort study of 3583 adults undergoing isolated coronary artery bypass grafting between 2008 and 2022 at 2 tertiary hospital centers. Operative and perioperative data were obtained from the institutional Society of Thoracic Surgeons database. Propensity score overlap weighting was used to balance baseline covariates. A 2-phase (30-day perioperative and 10-year chronic) Markov state-transition model, informed by weighted institutional outcomes and supplemented with national Society of Thoracic Surgeons and Centers for Medicare &amp; Medicaid Services data, was used to estimate long-term costs and quality-adjusted life years.</div></div><div><h3>Results</h3><div>Among 3583 patients at 2 academic centers, MAG was associated with similar operative mortality and morbidity compared with SAG. In a linked perioperative-chronic Markov model, MAG yielded greater quality-adjusted survival (+0.241 quality-adjusted life-years) and lower 10-year discounted costs (–$7755 per patient). Sensitivity analyses demonstrated that MAG was not consistently cost-effective in the perioperative period but was robustly dominant in the chronic phase, with long-term results stable across a wide range of cost assumptions.</div></div><div><h3>Conclusions</h3><div>MAG was associated with comparable perioperative outcomes but improved quality-adjusted survival and lower long-term costs compared with SAG. Broader adoption of MAG could reduce health care expenditures while improving population health by addressing barriers to MAG use, particularly in women, minority patients, and socially vulnerable populations.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101834"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disease-specific emotional burden persists after surgical repair for thoracic aortic aneurysm 胸主动脉瘤手术修复后疾病特异性情绪负担持续存在
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-05-20 DOI: 10.1016/j.xjon.2026.101865
Maeve M. Sargeant MA, Samantha McCrary MS, Ekin C. Uzunoglu MD, Elizabeth Jordan MA, Phoebe Jollay-Castelblanco BS, Erica Barwick FNP-C, Benjamin C. Degner MD, Samuel F. Sears PhD
{"title":"Disease-specific emotional burden persists after surgical repair for thoracic aortic aneurysm","authors":"Maeve M. Sargeant MA,&nbsp;Samantha McCrary MS,&nbsp;Ekin C. Uzunoglu MD,&nbsp;Elizabeth Jordan MA,&nbsp;Phoebe Jollay-Castelblanco BS,&nbsp;Erica Barwick FNP-C,&nbsp;Benjamin C. Degner MD,&nbsp;Samuel F. Sears PhD","doi":"10.1016/j.xjon.2026.101865","DOIUrl":"10.1016/j.xjon.2026.101865","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101865"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
On the interpretation of pleural clearance in imaging pathology correlation studies 胸膜间隙在影像学病理相关性研究中的解释
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-05-08 DOI: 10.1016/j.xjon.2026.101857
Ayşegül Güler MD, Arif Hakan Önder MD, Nilay Çavuşoğlu Yalçın MD
{"title":"On the interpretation of pleural clearance in imaging pathology correlation studies","authors":"Ayşegül Güler MD,&nbsp;Arif Hakan Önder MD,&nbsp;Nilay Çavuşoğlu Yalçın MD","doi":"10.1016/j.xjon.2026.101857","DOIUrl":"10.1016/j.xjon.2026.101857","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101857"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of minimally invasive mitral valve surgery on early postoperative organ dysfunction 微创二尖瓣手术对术后早期脏器功能障碍的影响
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-06-05 DOI: 10.1016/j.xjon.2026.101887
Rafael Maniés Pereira MSc, Beatriz Draiblate MD, Francisca Montenegro MD, Margarida Rocha MD, Nuno Guerra MD, Ricardo Ferreira MD, PhD, Ângelo Nobre MD, Luís Ferreira Moita MD, PhD, Tiago R. Velho MD, PhD
<div><h3>Objective</h3><div>The use of a minimally invasive approach in mitral valve surgery is increasing; however, its impact on early organ dysfunction and hemodynamic support remains debated. This study compared postoperative organ dysfunction, assessed by the Sequential Organ Failure Assessment score and the maximum vasoactive-inotropic score at 24 hours, between the minimally invasive approach in mitral valve surgery and sternotomy.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed of all consecutive patients undergoing mitral valve surgery at a single center. Patients were stratified according to surgical approach (minimally invasive approach in mitral valve surgery vs sternotomy). Primary outcomes were Sequential Organ Failure Assessment and maximum vasoactive-inotropic score at 24 hours. Group comparisons were performed using nonparametric tests, and multivariable regression models were adjusted for demographics and clinical covariates. A propensity score–matched sensitivity analysis was also performed.</div></div><div><h3>Results</h3><div>A total of 710 patients were included, 275 undergoing the minimally invasive approach in mitral valve surgery and 435 undergoing sternotomy. Median Sequential Organ Failure Assessment at 24 hours was lower after the minimally invasive approach in mitral valve surgery (4 [interquartile range, 2-6] vs 5 [interquartile range, 3-9], <em>P</em> < .001), and fewer patients undergoing the minimally invasive approach in mitral valve surgery had Sequential Organ Failure Assessment of 5 or more (43.6% vs 58.6%). On multivariable analysis, the minimally invasive approach in mitral valve surgery was independently associated with lower odds of elevated Sequential Organ Failure Assessment (odds ratio, 0.24, 95% CI, 0.15-0.37, <em>P</em> < .001). Maximum vasoactive-inotropic score at 24 hours was also lower after the minimally invasive approach in mitral valve surgery, with fewer patients presenting a maximum vasoactive-inotropic score at 24 hours of 13 or more (44.7% vs 56.1%); the minimally invasive approach in mitral valve surgery remained associated with lower odds of an elevated maximum vasoactive-inotropic score at 24 hours (odds ratio, 0.34, 95% CI, 0.22-0.51, <em>P</em> < .001). In the propensity score–matched cohort, the minimally invasive approach in mitral valve surgery remained associated with lower Sequential Organ Failure Assessment at 24 hours (mean difference, −2.64; 95% CI, −3.81 to −1.47; <em>P</em> < .0001), lower maximum vasoactive-inotropic score at 24 hours (mean difference, −23.82; 95% CI, −39.44 to −8.2; <em>P</em> = .003), lower odds of Sequential Organ Failure Assessment of 5 or more (odds ratio, 0.35; 95% CI, 0.2-0.63; <em>P</em> < .001), and lower odds of maximum vasoactive-inotropic score at 24 hours of 13 or more (odds ratio, 0.56; 95% CI, 0.33-0.97; <em>P</em> = .039). Differences were also observed across individual Sequential Organ Failure Asse
目的微创入路在二尖瓣手术中的应用越来越多;然而,其对早期器官功能障碍和血流动力学支持的影响仍存在争议。本研究比较了微创二尖瓣手术和胸骨切开术的术后器官功能障碍,通过序贯器官衰竭评估评分和24小时最大血管活性-肌力评分来评估。方法对在同一中心连续行二尖瓣手术的患者进行回顾性分析。根据手术入路(微创二尖瓣手术与胸骨切开术)对患者进行分层。主要结果是序贯器官衰竭评估和24小时最大血管活性-肌力评分。采用非参数检验进行组间比较,并根据人口统计学和临床协变量调整多变量回归模型。还进行了倾向评分匹配的敏感性分析。结果共纳入710例患者,其中微创二尖瓣入路275例,胸骨切开术435例。微创入路二尖瓣手术后24小时序贯器官衰竭评估中位数较低(4[四分位数范围,2-6]vs 5[四分位数范围,3-9],P < 001),微创入路二尖瓣手术患者序贯器官衰竭评估5及以上的患者较少(43.6% vs 58.6%)。在多变量分析中,二尖瓣手术的微创入路与序贯器官衰竭评估升高的几率较低独立相关(优势比,0.24,95% CI, 0.15-0.37, P < 0.001)。二尖瓣手术微创入路后24小时最大血管活性-肌力评分也较低,24小时最大血管活性-肌力评分为13或更高的患者较少(44.7% vs 56.1%);二尖瓣手术微创入路仍与24小时最大血管活性-肌力评分升高的几率较低相关(优势比0.34,95% CI, 0.22-0.51, P < 0.001)。在倾向评分匹配的队列中,二尖瓣手术的微创入路仍然与24小时较低的序贯器官衰竭评估相关(平均差值为- 2.64,95% CI为- 3.81至- 1.47,P < 0.0001), 24小时较低的血管活性-肌力评分(平均差值为- 23.82,95% CI为- 39.44至- 8.2,P = 0.003),序贯器官衰竭评估的较低几率为5或以上(优势比为0.35,95% CI为0.2-0.63;P < .001), 13岁或以上24小时血管活性-肌力评分最高的几率较低(优势比0.56;95% CI, 0.33-0.97; P = 0.039)。在各个顺序器官衰竭评估组成部分中也观察到差异,其中心血管、肾脏和神经领域的差异最大。结论在这项大型单中心队列研究中,与胸骨切开术相比,微创二尖瓣手术早期器官功能障碍较低,血管活性-肌力支持减少。在多变量调整和倾向评分匹配后,这些发现是一致的,并支持微创二尖瓣手术早期更有利的术后生理特征。
{"title":"The impact of minimally invasive mitral valve surgery on early postoperative organ dysfunction","authors":"Rafael Maniés Pereira MSc,&nbsp;Beatriz Draiblate MD,&nbsp;Francisca Montenegro MD,&nbsp;Margarida Rocha MD,&nbsp;Nuno Guerra MD,&nbsp;Ricardo Ferreira MD, PhD,&nbsp;Ângelo Nobre MD,&nbsp;Luís Ferreira Moita MD, PhD,&nbsp;Tiago R. Velho MD, PhD","doi":"10.1016/j.xjon.2026.101887","DOIUrl":"10.1016/j.xjon.2026.101887","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;The use of a minimally invasive approach in mitral valve surgery is increasing; however, its impact on early organ dysfunction and hemodynamic support remains debated. This study compared postoperative organ dysfunction, assessed by the Sequential Organ Failure Assessment score and the maximum vasoactive-inotropic score at 24 hours, between the minimally invasive approach in mitral valve surgery and sternotomy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;A retrospective analysis was performed of all consecutive patients undergoing mitral valve surgery at a single center. Patients were stratified according to surgical approach (minimally invasive approach in mitral valve surgery vs sternotomy). Primary outcomes were Sequential Organ Failure Assessment and maximum vasoactive-inotropic score at 24 hours. Group comparisons were performed using nonparametric tests, and multivariable regression models were adjusted for demographics and clinical covariates. A propensity score–matched sensitivity analysis was also performed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;A total of 710 patients were included, 275 undergoing the minimally invasive approach in mitral valve surgery and 435 undergoing sternotomy. Median Sequential Organ Failure Assessment at 24 hours was lower after the minimally invasive approach in mitral valve surgery (4 [interquartile range, 2-6] vs 5 [interquartile range, 3-9], &lt;em&gt;P&lt;/em&gt; &lt; .001), and fewer patients undergoing the minimally invasive approach in mitral valve surgery had Sequential Organ Failure Assessment of 5 or more (43.6% vs 58.6%). On multivariable analysis, the minimally invasive approach in mitral valve surgery was independently associated with lower odds of elevated Sequential Organ Failure Assessment (odds ratio, 0.24, 95% CI, 0.15-0.37, &lt;em&gt;P&lt;/em&gt; &lt; .001). Maximum vasoactive-inotropic score at 24 hours was also lower after the minimally invasive approach in mitral valve surgery, with fewer patients presenting a maximum vasoactive-inotropic score at 24 hours of 13 or more (44.7% vs 56.1%); the minimally invasive approach in mitral valve surgery remained associated with lower odds of an elevated maximum vasoactive-inotropic score at 24 hours (odds ratio, 0.34, 95% CI, 0.22-0.51, &lt;em&gt;P&lt;/em&gt; &lt; .001). In the propensity score–matched cohort, the minimally invasive approach in mitral valve surgery remained associated with lower Sequential Organ Failure Assessment at 24 hours (mean difference, −2.64; 95% CI, −3.81 to −1.47; &lt;em&gt;P&lt;/em&gt; &lt; .0001), lower maximum vasoactive-inotropic score at 24 hours (mean difference, −23.82; 95% CI, −39.44 to −8.2; &lt;em&gt;P&lt;/em&gt; = .003), lower odds of Sequential Organ Failure Assessment of 5 or more (odds ratio, 0.35; 95% CI, 0.2-0.63; &lt;em&gt;P&lt;/em&gt; &lt; .001), and lower odds of maximum vasoactive-inotropic score at 24 hours of 13 or more (odds ratio, 0.56; 95% CI, 0.33-0.97; &lt;em&gt;P&lt;/em&gt; = .039). Differences were also observed across individual Sequential Organ Failure Asse","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101887"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The treatment intensity paradox in stable coronary artery disease: When upstream escalation depletes surgical durability 稳定性冠状动脉疾病的治疗强度悖论:当上游升级耗尽手术持久性
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-04-30 DOI: 10.1016/j.xjon.2026.101848
Jeffrey H. Shuhaiber MD, MBA
{"title":"The treatment intensity paradox in stable coronary artery disease: When upstream escalation depletes surgical durability","authors":"Jeffrey H. Shuhaiber MD, MBA","doi":"10.1016/j.xjon.2026.101848","DOIUrl":"10.1016/j.xjon.2026.101848","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101848"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing cyanotic neonates with tetralogy of Fallot: A national perspective on surgical approaches 处理患有法洛四联症的紫绀新生儿:手术方法的全国视角
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-04-07 DOI: 10.1016/j.xjon.2026.101745
Samuel M. Hoenig BA, David Bruckman MS, Karl F. Welke MD, MS, Justin Robinson MD, MS, Anusha Jegatheeswaran MD, PhD, Rashed Mahboubi MD, Belinda Udeh PhD, Jarod Dalton PhD, Md M. Hossain MSc, PhD, Tara Karamlou MD, MSc

Objective

Management of cyanotic neonates with tetralogy of Fallot (ToF) remains an important clinical challenge without Level 1 evidence. The present study employs the Healthcare Cost and Utilization Project Kids Inpatient Dataset to evaluate a national sample of neonates undergoing intervention for ToF.

Methods

A 4-stage algorithm was designed to capture records for neonates with ToF who underwent primary repair, ductal stents, and systemic-to-pulmonary shunts in the Healthcare Cost and Utilization Project Kids Inpatient Dataset (2016, 2019, and 2022). National hospitalization estimates and percent reported reflect weighted results based on survey design. Resource utilization was represented by median hospital length of stay and inflation-adjusted cost in 2023 US dollars.

Results

An estimated 159.5 discharges were identified for primary repair, 145.3 for ductal stents, and 407.4 for surgical systemic to pulmonary shunts. An estimated 256.3 discharges were identified for infants undergoing definitive repairs following ductal stents. From 2016 to 2022, ductal stent utilization increased (linear trend P = .0011), whereas surgical shunt use decreased (trend P = .0012). There was a trend toward a decrease in primary repair (trend P= .12). Over this time frame, there was a significant increase in the median cost for ductal stent (difference, $77,252 [2023 dollars], P = .035) and surgical shunt (difference, $81,111 [2023 dollars]; P = .043) palliations and a decrease in primary repair cost (difference, $76,337 [2023 dollars]; P = .44).

Conclusions

This investigation demonstrated increased utilization of ductal stents for neonatal ToF across the United States. Despite this increase, changes in cost may reflect a complex paradigm shift in patient/center-specific decision making.
目的在没有一级证据的情况下,对患有法洛四联症(ToF)的紫绀新生儿的治疗仍然是一个重要的临床挑战。本研究采用医疗保健成本和利用项目儿童住院病人数据集来评估接受ToF干预的全国新生儿样本。方法设计一个4阶段算法,以获取医疗成本和利用项目儿童住院患者数据集(2016年、2019年和2022年)中接受初级修复、导管支架和系统-肺分流术的ToF新生儿的记录。全国住院估计和报告的百分比反映了基于调查设计的加权结果。资源利用以2023年美元计算的住院时间中位数和通货膨胀调整后的成本为代表。结果估计有159.5例因初级修复而出院,145.3例因导管支架而出院,407.4例因手术系统到肺分流而出院。估计有256.3例婴儿在导管支架后接受最终修复。2016 - 2022年,导管支架使用率上升(线性趋势P = 0.0011),手术分流使用率下降(线性趋势P = 0.0012)。原发性修复有减少的趋势(P= .12)。在这段时间内,导管支架(差异,77,252美元[2023美元],P = 0.035)和手术分流(差异,81,111美元[2023美元],P = 0.043)姑息治疗的中位数成本显著增加,初级修复成本下降(差异,76,337美元[2023美元],P = 0.44)。结论:在美国,导管支架在新生儿ToF治疗中的应用有所增加。尽管这一增长,但成本的变化可能反映了患者/中心特定决策的复杂模式转变。
{"title":"Managing cyanotic neonates with tetralogy of Fallot: A national perspective on surgical approaches","authors":"Samuel M. Hoenig BA,&nbsp;David Bruckman MS,&nbsp;Karl F. Welke MD, MS,&nbsp;Justin Robinson MD, MS,&nbsp;Anusha Jegatheeswaran MD, PhD,&nbsp;Rashed Mahboubi MD,&nbsp;Belinda Udeh PhD,&nbsp;Jarod Dalton PhD,&nbsp;Md M. Hossain MSc, PhD,&nbsp;Tara Karamlou MD, MSc","doi":"10.1016/j.xjon.2026.101745","DOIUrl":"10.1016/j.xjon.2026.101745","url":null,"abstract":"<div><h3>Objective</h3><div>Management of cyanotic neonates with tetralogy of Fallot (ToF) remains an important clinical challenge without Level 1 evidence. The present study employs the Healthcare Cost and Utilization Project Kids Inpatient Dataset to evaluate a national sample of neonates undergoing intervention for ToF.</div></div><div><h3>Methods</h3><div>A 4-stage algorithm was designed to capture records for neonates with ToF who underwent primary repair, ductal stents, and systemic-to-pulmonary shunts in the Healthcare Cost and Utilization Project Kids Inpatient Dataset (2016, 2019, and 2022). National hospitalization estimates and percent reported reflect weighted results based on survey design. Resource utilization was represented by median hospital length of stay and inflation-adjusted cost in 2023 US dollars.</div></div><div><h3>Results</h3><div>An estimated 159.5 discharges were identified for primary repair, 145.3 for ductal stents, and 407.4 for surgical systemic to pulmonary shunts. An estimated 256.3 discharges were identified for infants undergoing definitive repairs following ductal stents. From 2016 to 2022, ductal stent utilization increased (linear trend <em>P</em> = .0011), whereas surgical shunt use decreased (trend <em>P</em> = .0012). There was a trend toward a decrease in primary repair (trend <em>P</em>= .12). Over this time frame, there was a significant increase in the median cost for ductal stent (difference, $77,252 [2023 dollars], <em>P</em> = .035) and surgical shunt (difference, $81,111 [2023 dollars]; <em>P</em> = .043) palliations and a decrease in primary repair cost (difference, $76,337 [2023 dollars]; <em>P</em> = .44).</div></div><div><h3>Conclusions</h3><div>This investigation demonstrated increased utilization of ductal stents for neonatal ToF across the United States. Despite this increase, changes in cost may reflect a complex paradigm shift in patient/center-specific decision making.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101745"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immediate postoperative biomarkers characterize severity of primary graft dysfunction after heart transplantation 心脏移植后立即术后生物标志物表征原发性移植物功能障碍的严重程度
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-05-13 DOI: 10.1016/j.xjon.2026.101863
Shreyas Kiran BS, Phoebe Miller MS, MD, Isha Maniyar BS, Jashdeep Dhillon BA, Sarah Sullivan BS, Andrew Akcelik MD, Amy G. Fiedler MD, Jason Smith MD

Objective

Primary graft dysfunction (PGD) remains the leading cause of early morbidity and mortality after orthotopic heart transplantation. Postoperative lactate and the venoarterial carbon dioxide gap (Pv-a CO2) are routinely measured indicators of hypoperfusion, yet their relationship to PGD severity is not well characterized. This study evaluated the association between immediate posttransplant (T0) and 24-hour (T24) biomarker values and the severity of PGD.

Methods

We performed a single-center retrospective study of adult recipients of orthotopic heart transplantation (May 2020 to May 2023). PGD was defined according to International Society for Heart and Lung Transplantation criteria and categorized as none, moderate, or severe. Pv-a CO2 and serum lactate were collected at T0 for multivariable analysis and at T24 for descriptive and exploratory modeling. Patients receiving a simultaneous heart-lung transplant were excluded. Multivariable logistic regressions adjusted for age, body mass index, and sex.

Results

Among 110 recipients, PGD occurred in 50 (45%) cases, including 39 moderate and 11 severe. At T0, both biomarkers demonstrated stepwise increases with PGD severity. Each 1-mm Hg increase in Pv-a CO2 was associated with greater odds of any PGD (odds ratio [OR], 1.53; 95% CI, 1.22-1.92), moderate PGD (OR, 1.48; 95% CI, 1.15-1.92), and severe PGD (OR, 2.07; 95% CI, 1.45-2.97). T0 lactate was independently associated with moderate PGD (OR, 1.21; 95% CI, 1.03-1.43). By 24 hours, Pv-a CO2 no longer independently differentiated PGD severity, whereas T24 lactate remained associated with moderate PGD (OR, 1.68; 95% CI, 1.13-2.49).

Conclusions

Immediate posttransplant Pv-a CO2 is a strong discriminator of PGD severity and may serve as an early, objective adjunct to International Society for Heart and Lung Transplantation criteria. In contrast, lactate reflects both initial hypoperfusion and the subsequent trajectory of metabolic recovery, with persistent elevations at 24 hours indicating ongoing physiologic stress. Together, these readily available biomarkers provide complementary information that may improve early diagnostic stratification of PGD.
目的原发性移植物功能障碍(PGD)仍然是原位心脏移植术后早期发病和死亡的主要原因。术后乳酸和静脉动脉二氧化碳间隙(Pv-a CO2)是常规测量灌注不足的指标,但它们与PGD严重程度的关系尚未得到很好的表征。本研究评估移植后即刻(T0)和24小时(T24)生物标志物值与PGD严重程度之间的关系。方法对成人原位心脏移植受者(2020年5月至2023年5月)进行单中心回顾性研究。PGD是根据国际心肺移植学会的标准定义的,分为无、中度和重度。在T0收集Pv-a CO2和血清乳酸进行多变量分析,在T24进行描述性和探索性建模。同时接受心肺移植的患者被排除在外。多变量logistic回归校正了年龄、体重指数和性别。结果110例患者中发生PGD 50例(45%),其中中度39例,重度11例。在T0时,两种生物标志物均随PGD严重程度逐步增加。Pv-a CO2浓度每升高1毫米汞柱,任何PGD(比值比[OR], 1.53; 95% CI, 1.22-1.92)、中度PGD (OR, 1.48; 95% CI, 1.15-1.92)和重度PGD (OR, 2.07; 95% CI, 1.45-2.97)的几率均增加。T0乳酸与中度PGD独立相关(OR, 1.21; 95% CI, 1.03-1.43)。到24小时,Pv-a CO2不再独立区分PGD严重程度,而T24乳酸仍然与中度PGD相关(OR, 1.68; 95% CI, 1.13-2.49)。结论移植后即刻Pv-a CO2是判断PGD严重程度的有力指标,可作为国际心肺移植学会早期、客观的辅助标准。相反,乳酸反映了最初的低灌注和随后的代谢恢复轨迹,24小时内持续升高表明持续的生理应激。总之,这些现成的生物标志物提供了补充信息,可以改善PGD的早期诊断分层。
{"title":"Immediate postoperative biomarkers characterize severity of primary graft dysfunction after heart transplantation","authors":"Shreyas Kiran BS,&nbsp;Phoebe Miller MS, MD,&nbsp;Isha Maniyar BS,&nbsp;Jashdeep Dhillon BA,&nbsp;Sarah Sullivan BS,&nbsp;Andrew Akcelik MD,&nbsp;Amy G. Fiedler MD,&nbsp;Jason Smith MD","doi":"10.1016/j.xjon.2026.101863","DOIUrl":"10.1016/j.xjon.2026.101863","url":null,"abstract":"<div><h3>Objective</h3><div>Primary graft dysfunction (PGD) remains the leading cause of early morbidity and mortality after orthotopic heart transplantation. Postoperative lactate and the venoarterial carbon dioxide gap (Pv-a CO<sub>2</sub>) are routinely measured indicators of hypoperfusion, yet their relationship to PGD severity is not well characterized. This study evaluated the association between immediate posttransplant (T0) and 24-hour (T24) biomarker values and the severity of PGD.</div></div><div><h3>Methods</h3><div>We performed a single-center retrospective study of adult recipients of orthotopic heart transplantation (May 2020 to May 2023). PGD was defined according to International Society for Heart and Lung Transplantation criteria and categorized as none, moderate, or severe. Pv-a CO<sub>2</sub> and serum lactate were collected at T0 for multivariable analysis and at T24 for descriptive and exploratory modeling. Patients receiving a simultaneous heart-lung transplant were excluded. Multivariable logistic regressions adjusted for age, body mass index, and sex.</div></div><div><h3>Results</h3><div>Among 110 recipients, PGD occurred in 50 (45%) cases, including 39 moderate and 11 severe. At T0, both biomarkers demonstrated stepwise increases with PGD severity. Each 1-mm Hg increase in Pv-a CO<sub>2</sub> was associated with greater odds of any PGD (odds ratio [OR], 1.53; 95% CI, 1.22-1.92), moderate PGD (OR, 1.48; 95% CI, 1.15-1.92), and severe PGD (OR, 2.07; 95% CI, 1.45-2.97). T0 lactate was independently associated with moderate PGD (OR, 1.21; 95% CI, 1.03-1.43). By 24 hours, Pv-a CO<sub>2</sub> no longer independently differentiated PGD severity, whereas T24 lactate remained associated with moderate PGD (OR, 1.68; 95% CI, 1.13-2.49).</div></div><div><h3>Conclusions</h3><div>Immediate posttransplant Pv-a CO<sub>2</sub> is a strong discriminator of PGD severity and may serve as an early, objective adjunct to International Society for Heart and Lung Transplantation criteria. In contrast, lactate reflects both initial hypoperfusion and the subsequent trajectory of metabolic recovery, with persistent elevations at 24 hours indicating ongoing physiologic stress. Together, these readily available biomarkers provide complementary information that may improve early diagnostic stratification of PGD.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101863"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simulation-based modeling of aortic valve neocuspidization with oversized pericardial leaflets 心包小叶过大主动脉瓣新瓣化的模拟建模
IF 2.2 Pub Date : 2026-08-01 Epub Date: 2026-05-04 DOI: 10.1016/j.xjon.2026.101806
Jalal Cherkaoui MEng, Ines A. Martínez MD, Yassine Toufique PhD, James D. St Louis MD, Mohammed Cherkaoui PhD, Ignacio Lugones MD, PhD

Objective

Aortic valve replacement in children is challenging. The lack of accommodation for somatic growth negatively impacts long-term outcomes. Data on the use of symmetrical oversized leaflets in neocuspidization are limited. We present a computer-based simulation of patient growth after a replacement with an oversized aortic valve leaflet.

Methods

A new aortic valve design was modeled in silico. Three computer-simulated symmetrical leaflets, each 18 mm in nominal width, were constructed for 4 simulated aortic roots with different diameters (12, 14, 16, and 18 mm). Pressure was applied to the aortic root side to simulate diastolic pressure and valve closure. The morphology of the closed valve was evaluated across different settings to examine morphologic changes during somatic growth. Three parameters of oversizing, previously described in our in vitro and in vivo studies, were assessed across the simulations: windmill shape deviation, coaptation length, and billow below the annular plane distance.

Results

A decrease in oversizing parameters was observed as the diameter of the aortic root increased. The average deviation from the windmill shape, the coaptation length, and the distance from the annular plane to the leaflet billow all decreased consistently with growth, indicating morphological adaptation of the valve geometry. These correlated changes suggest that the valve design adapts to anatomical growth by altering its functional configuration without compromising coaptation.

Conclusions

Achieving optimal outcomes in aortic valve replacement in children remains challenging. Neocuspidization with oversized aortic valve leaflets addresses important limitations of current valve replacement techniques. Larger leaflets support growth by maintaining proper coaptation.
目的:儿童主动脉瓣置换术具有挑战性。缺乏对躯体生长的适应会对长期结果产生负面影响。在新尖化中使用对称的超大小叶的数据是有限的。我们提出了一个基于计算机的模拟患者生长后,更换了一个超大的主动脉瓣小叶。方法采用计算机模拟新型主动脉瓣设计。为4个不同直径(12、14、16和18 mm)的模拟主动脉根部构建3个计算机模拟对称小叶,每个公称宽度为18 mm。在主动脉根侧施加压力以模拟舒张压和瓣膜关闭。在不同的设置中评估关闭阀门的形态,以检查体细胞生长过程中的形态变化。我们在体外和体内研究中描述的三个超大尺寸参数在模拟中进行了评估:风车形状偏差、适应长度和环形平面距离以下的波浪。结果随着主动脉根部直径的增加,主动脉过径参数降低。与风车形状的平均偏差、适应长度和从环面到小叶浪头的距离均随生长而一致减小,表明瓣膜几何形状发生了形态适应。这些相关的变化表明,瓣膜设计通过改变其功能配置而不影响适应性来适应解剖生长。结论在儿童主动脉瓣置换术中获得最佳结果仍然具有挑战性。主动脉瓣瓣叶过大的新瓣膜置换术解决了当前瓣膜置换术的重要局限性。较大的小叶通过保持适当的适应来支持生长。
{"title":"Simulation-based modeling of aortic valve neocuspidization with oversized pericardial leaflets","authors":"Jalal Cherkaoui MEng,&nbsp;Ines A. Martínez MD,&nbsp;Yassine Toufique PhD,&nbsp;James D. St Louis MD,&nbsp;Mohammed Cherkaoui PhD,&nbsp;Ignacio Lugones MD, PhD","doi":"10.1016/j.xjon.2026.101806","DOIUrl":"10.1016/j.xjon.2026.101806","url":null,"abstract":"<div><h3>Objective</h3><div>Aortic valve replacement in children is challenging. The lack of accommodation for somatic growth negatively impacts long-term outcomes. Data on the use of symmetrical oversized leaflets in neocuspidization are limited. We present a computer-based simulation of patient growth after a replacement with an oversized aortic valve leaflet.</div></div><div><h3>Methods</h3><div>A new aortic valve design was modeled in silico. Three computer-simulated symmetrical leaflets, each 18 mm in nominal width, were constructed for 4 simulated aortic roots with different diameters (12, 14, 16, and 18 mm). Pressure was applied to the aortic root side to simulate diastolic pressure and valve closure. The morphology of the closed valve was evaluated across different settings to examine morphologic changes during somatic growth. Three parameters of oversizing, previously described in our in vitro and in vivo studies, were assessed across the simulations: windmill shape deviation, coaptation length, and billow below the annular plane distance.</div></div><div><h3>Results</h3><div>A decrease in oversizing parameters was observed as the diameter of the aortic root increased. The average deviation from the windmill shape, the coaptation length, and the distance from the annular plane to the leaflet billow all decreased consistently with growth, indicating morphological adaptation of the valve geometry. These correlated changes suggest that the valve design adapts to anatomical growth by altering its functional configuration without compromising coaptation.</div></div><div><h3>Conclusions</h3><div>Achieving optimal outcomes in aortic valve replacement in children remains challenging. Neocuspidization with oversized aortic valve leaflets addresses important limitations of current valve replacement techniques. Larger leaflets support growth by maintaining proper coaptation.</div></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":"32 ","pages":"Article 101806"},"PeriodicalIF":2.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148704085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JTCVS open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1